CA2902498F - Utilisation de sel d'acide benzoique dans la fabrication d'une composition destinee a prevenir ou traiter la demence ou un trouble cognitif leger - Google Patents
Utilisation de sel d'acide benzoique dans la fabrication d'une composition destinee a prevenir ou traiter la demence ou un trouble cognitif leger Download PDFInfo
- Publication number
- CA2902498F CA2902498F CA2902498A CA2902498A CA2902498F CA 2902498 F CA2902498 F CA 2902498F CA 2902498 A CA2902498 A CA 2902498A CA 2902498 A CA2902498 A CA 2902498A CA 2902498 F CA2902498 F CA 2902498F
- Authority
- CA
- Canada
- Prior art keywords
- day
- use according
- benzoic acid
- acid salt
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 48
- 206010012289 Dementia Diseases 0.000 title claims abstract description 45
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 44
- 150000001558 benzoic acid derivatives Chemical class 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 50
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 60
- 235000010234 sodium benzoate Nutrition 0.000 claims description 57
- 239000004299 sodium benzoate Substances 0.000 claims description 57
- 235000010237 calcium benzoate Nutrition 0.000 claims description 5
- 239000004301 calcium benzoate Substances 0.000 claims description 5
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 claims description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 5
- 235000010235 potassium benzoate Nutrition 0.000 claims description 5
- 239000004300 potassium benzoate Substances 0.000 claims description 5
- 229940103091 potassium benzoate Drugs 0.000 claims description 5
- 229940126701 oral medication Drugs 0.000 claims 8
- 238000011282 treatment Methods 0.000 description 31
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 28
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 28
- 239000000902 placebo Substances 0.000 description 28
- 229940068196 placebo Drugs 0.000 description 28
- 230000000694 effects Effects 0.000 description 24
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 230000019771 cognition Effects 0.000 description 18
- 239000002131 composite material Substances 0.000 description 18
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 15
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 15
- 230000015654 memory Effects 0.000 description 13
- 230000013016 learning Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 9
- 229930195711 D-Serine Natural products 0.000 description 9
- 229940050390 benzoate Drugs 0.000 description 9
- 230000001755 vocal effect Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000003936 working memory Effects 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000001149 cognitive effect Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 238000001521 two-tailed test Methods 0.000 description 6
- 238000000585 Mann–Whitney U test Methods 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000001638 cerebellum Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004129 prosencephalon Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 208000030251 communication disease Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 1
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010988 intraclass correlation coefficient Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000020796 long term synaptic depression Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007979 neuropsychological functioning Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 230000026797 positive regulation of anti-apoptosis Effects 0.000 description 1
- 230000015284 positive regulation of neurogenesis Effects 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000003414 procognitive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- -1 sodium benzoate Chemical class 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG2014/000140 WO2015147742A1 (fr) | 2014-03-24 | 2014-03-24 | Utilisation d'un sel d'acide benzoïque dans la fabrication d'une composition pour prévenir ou traiter la démence ou un trouble cognitif léger |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| CA2902498F true CA2902498F (fr) | 2015-09-24 |
| CA2902498A1 CA2902498A1 (fr) | 2015-09-24 |
| CA2902498C CA2902498C (fr) | 2017-03-28 |
Family
ID=54196083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2902498A Active CA2902498C (fr) | 2014-03-24 | 2014-03-24 | Utilisation de sel d'acide benzoique dans la fabrication d'une composition destinee a prevenir ou traiter la demence ou un trouble cognitif leger |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2016517866A (fr) |
| KR (2) | KR102162073B1 (fr) |
| AU (1) | AU2014386718B8 (fr) |
| CA (1) | CA2902498C (fr) |
| DE (1) | DE212014000063U1 (fr) |
| SG (1) | SG11201507188QA (fr) |
| WO (1) | WO2015147742A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3027297A1 (fr) * | 2016-06-13 | 2017-12-21 | Syneurx International (Taiwan) Corp. | Co-cristaux de benzoate de sodium et leurs utilisations |
| RU2022101542A (ru) * | 2016-06-13 | 2022-02-03 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| SG11201907324VA (en) | 2017-03-03 | 2019-09-27 | Excelsior Pharmatech Labs | Method for preventing or treating autism spectrum disorders by benzoic acid salt |
| WO2019103597A1 (fr) * | 2017-11-22 | 2019-05-31 | Excelsior Pharmatech Labs | Acide benzoïque ou sel et dérivé de celui-ci destiné à être utilisé dans la prévention ou le traitement de la dépression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| BRPI0417910A (pt) * | 2003-12-29 | 2007-04-10 | Sepracor Inc | composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto |
| EP3006024B1 (fr) * | 2009-01-20 | 2019-03-20 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Acide benzoïque ou de ses sels pour améliorer l'action d'un produit neuropharmaceutique |
| GB201111704D0 (en) * | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| PE20141361A1 (es) * | 2011-11-15 | 2014-10-13 | Takeda Pharmaceutical | Compuesto heterociclico dihidroxi aromatico |
-
2014
- 2014-03-24 KR KR1020177024853A patent/KR102162073B1/ko active IP Right Grant
- 2014-03-24 WO PCT/SG2014/000140 patent/WO2015147742A1/fr active Application Filing
- 2014-03-24 KR KR1020167003184A patent/KR20160029837A/ko not_active Application Discontinuation
- 2014-03-24 CA CA2902498A patent/CA2902498C/fr active Active
- 2014-03-24 SG SG11201507188QA patent/SG11201507188QA/en unknown
- 2014-03-24 JP JP2016510654A patent/JP2016517866A/ja active Pending
- 2014-03-24 AU AU2014386718A patent/AU2014386718B8/en active Active
- 2014-03-24 DE DE212014000063.7U patent/DE212014000063U1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160029837A (ko) | 2016-03-15 |
| CA2902498A1 (fr) | 2015-09-24 |
| CA2902498C (fr) | 2017-03-28 |
| DE212014000063U1 (de) | 2015-10-12 |
| AU2014386718B8 (en) | 2017-12-07 |
| AU2014386718A1 (en) | 2015-10-08 |
| AU2014386718A8 (en) | 2017-12-07 |
| SG11201507188QA (en) | 2015-10-29 |
| AU2014386718B2 (en) | 2017-07-20 |
| JP2016517866A (ja) | 2016-06-20 |
| KR20170104658A (ko) | 2017-09-15 |
| KR102162073B1 (ko) | 2020-10-07 |
| WO2015147742A1 (fr) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial | |
| CA2902498C (fr) | Utilisation de sel d'acide benzoique dans la fabrication d'une composition destinee a prevenir ou traiter la demence ou un trouble cognitif leger | |
| Joe et al. | Cognitive symptoms of Alzheimer’s disease: clinical management and prevention | |
| Bhandari et al. | Resveratrol suppresses neuroinflammation in the experimental paradigm of autism spectrum disorders | |
| Moretti et al. | Depression and Alzheimer's disease: symptom or comorbidity? | |
| Ferreri et al. | Motor cortex excitability in Alzheimer's disease: a transcranial magnetic stimulation follow-up study | |
| WO2011029176A1 (fr) | Préparation destinée a améliorer la concentration et les performances mentales | |
| US10130602B2 (en) | Use of L-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function | |
| JP6550426B2 (ja) | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 | |
| Bhattacharya et al. | Attention enhancing effects of methylphenidate are age-dependent | |
| TWI573588B (zh) | 苯甲酸鹽用於製備治療失智症或輕度認知障礙之醫藥組成物的用途 | |
| Parikh et al. | Current trends and updates in the treatment of Alzheimer's disease | |
| Reisberg et al. | Piracetam in the treatment of cognitive impairment in the elderly | |
| JP2008542263A (ja) | 認知能力改善薬 | |
| Zhu et al. | The Relieving Effects of BrainPower Advanced, a Dietary Supplement, in Older Adults with Subjective Memory Complaints: A Randomized, Double‐Blind, Placebo‐Controlled Trial | |
| US20240016875A1 (en) | Shan-zha for the treatment of depression and anxiety disorders | |
| US20170216234A1 (en) | Benzoates for use in treating dementia | |
| Mintzer | The search for better noncholinergic treatment options for Alzheimer's disease | |
| Öhman | Effect of exercise on cognition, physical functioning, fall rate, and neuropsychiatric symptoms in people with dementia | |
| Haworth | Gait, aging and dementia | |
| Ayati et al. | Advances in treatment of mild cognitive impairment (MCI) and dementia: A review of promising non-pharmaceutical modalities | |
| Shoghi et al. | Effects of moderate intensity training and lithium on spatial learning and memory in a rat model: The role of SIRT3 and PGC1-α expression levels and brain-derived neurotropic factor | |
| BR102022006625A2 (pt) | Suplemento alimentar e seu uso | |
| Lake et al. | Integrative assessment and treatment of cognitive impairment | |
| Oken | Non-prescription and non-pharmacological therapies for dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NARC | Re-examination certificate |
Effective date: 20181130 |
|
| NARC | Re-examination certificate |
Effective date: 20181130 |
|
| NARC | Re-examination certificate |
Effective date: 20181130 |